| [1] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231.
|
| [2] |
吴晓燕, 朱自力, 张金业. 肿瘤标志物检测在肺癌诊断中的临床应用价值探讨[J]. 检验医学, 2014, 29(5):578-580.
DOI
|
| [3] |
NAKAYAMA M, SATOH H, ISHIKAWA H, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases[J]. Chest, 2003, 123(6):2001-2006.
PMID
|
| [4] |
STIEBER P, HASHOLZNER U, BODENMÜLLER H, et al. CYFRA21-1:a new marker in lung cancer[J]. Cancer, 1993, 72(3):707-713.
DOI
URL
|
| [5] |
DOYLE K, BUNCH D R. Reference intervals:past,present,and future[J]. Crit Rev Clin Lab Sci, 2023, 60(6):466-482.
DOI
URL
|
| [6] |
JONES G R D, HAECKEL R, LOH T P, et al. Indirect methods for reference interval determination-review and recommendations[J]. Clin Chem Lab Med, 2018, 57(1):20-29.
DOI
URL
|
| [7] |
Clinical and Laboratory Standards Institute. Defining,establishing,and verifying reference intervals in the clinical laboratory;approved guideline-third edition[S]. EP28-A3c,CLSI, 2010.
|
| [8] |
中国抗癌协会肿瘤标志专业委员会. 中国人群肺癌血清标志物临床应用及参考区间建立规范化流程专家共识[J]. 中国肿瘤临床, 2021, 48(22):1135-1140.
|
| [9] |
中华人民共和国国家卫生健康委员会.WS/T 402—2024 临床实验室定量检验项目参考区间的制定[S]. 北京: 中华人民共和国国家卫生健康委员会, 2024.
|
| [10] |
KASHIWABARA K, KISHI K, NAKAMURA H, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure[J]. Intern Med, 1998, 37(11):917-921.
DOI
URL
|
| [11] |
STIEBER P, HOLDENRIEDER S. Lung cancer biomarkers-where we are and what we need[J]. Cancer Biomark, 2010, 6(3-4):221-224.
DOI
URL
|
| [12] |
CHEN S, LI M, WENG T, et al. Recent progress of biosensors for the detection of lung cancer markers[J]. J Mater Chem B, 2023, 11(25):5715-5747.
DOI
PMID
|
| [13] |
EBERT W, DIENEMANN H, FATEH-MOGHADAM A, et al. Cytokeratin 19 fragment CYFRA21-1 compared with carcinoembryonic antigen,squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study[J]. Eur J Clin Chem Clin Biochem, 1994, 32(3):189-199.
|
| [14] |
ZHAO B, ZHANG M, LIU D, et al. Establishment of reference interval for the tumour marker serum CYFRA21-1 in healthy Chinese Han ethnic adults[J]. Scand J Clin Lab Invest, 2018, 78(3):171-174.
DOI
URL
|
| [15] |
ZHEN S H, WANG Y, GU C G, et al. Establishment of reference intervals for serum cytokeratin-19 fragment and neuron specific enolase by indirect method using data obtained from healthy Chinese population in Chengdu[J]. Clin Lab, 2019, 65(8):1425-1430.
|
| [16] |
姬智, 邓玲艳, 李娇元, 等. 武汉地区健康成人血清细胞角蛋白19片段参考区间的建立[J]. 检验医学, 2021, 36(5):490-494.
DOI
|
| [17] |
YOON S, LIM Y K, KIM H R, et al. Establishment of reference intervals of cytokeratin 19 fragment antigen 21-1 in Korean adults[J]. Ann Lab Med, 2023, 43(1):82-85.
DOI
PMID
|
| [18] |
DAI Y, QU W, SANG S, et al. Reference intervals of cytokeratin-19 fragment(CYFRA21-1)in healthy adults in China[J]. Clin Lab, 2018, 64(1):123-133.
|